Our Services

Radionuclide Therapy

RADIUM 223 (XOFIGO)

Xofigo is the therapeutic alpha particle-emitting pharmaceutical that is indicated for the treatment of castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases and no known visceral metastatic disease. It is the first bone-targeted agent to extend overall survival and improve quality of life (QOL) in CRPC, with a favourable safety profile.

xofigo-targeted

TARGETED

Xofigo®  mimics calcium andselectively targets bone, specifically areas of bone metatases, by forming complexes with thebone mineral hydroxyapatite

xofigo-localized

LOCALIZED

The short range of alphaparticles emmited by Xofigo (<10 cell diameters) gives thema highly localized radius ofaction, minimizing damageto surrounding normal tissues

xofigo-potent

POTENT

Xofigo emits alpha particesthat lead to high frequency ofdouble-strand DNA breaks inadjacent tumor cells resulting ina potent cytotoxic effect onbone metatases

Benefits of Xofigo:

  • 30% reduction on the risk of death
    — 6 month increase in median overall survival (14.9 months vs 11.3 months)
  • 34% reduction on the risk of symptomatic skeletal events (SSEs)
    — Median time to first SSE was significantly delayed by 5.8 months vs placebo
  • The number of patients who had adverse events after they received the study drug was consistently lower in the Xofigo group than in the placebo group for all adverse events
  • Patients may return home immediately following injection, with no restrictions regarding contact with other people